Showing results (51-60 of 189) with videos related to
Sort By:
Pageof 19
European Urology|December 1, 1998
Involvement of the urogenital tract in patients with five or more separate malignant neoplasms. Case and reviewD Rohde, G JakseAktuelle Urologie|March 29, 2007
[Does plasmatic dilution influence the validity of PSA-tests?]D Rohde, V MihelcicUrologia Internationalis|January 1, 1996
Results of postchemotherapy adjunctive retroperitoneal lymph node dissection in non-seminomatous germ cell cancer patientsM Goepel, F Recker, T Otto, et al.European Urology|January 1, 1997
Phase II study: adjuvant single-agent carboplatin therapy for clinical stage I seminomaS Krege, G Kalund, T Otto, et al.Der Urologe. Ausg. A|February 21, 2006
["Second opinion centers". Approach for improving the quality of treatment for testicular tumors]M Schrader, M Hartmann, S Krege, et al.The Journal of Urology|December 23, 2000
Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 studyS Krege, V Rembrink, C Börgermann, et al.Der Urologe. Ausg. A|July 1, 1997
[Long-term outcome of surgical therapy of metastatic non-seminomatous germ cell tumor in advanced tumor stages]T Otto, S Krege, M Goepel, et al.The Journal of Urology|September 1, 1996
A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating ClinicsS Krege, G Giani, R Meyer, et al.Der Urologe. Ausg. A|July 14, 2004
[Geriatric assessment. Is it significantly helpful in selection of elderly tumour patients for a difficult therapy?]S Krege, C Friedrich, G Lümmen, et al.Der Urologe. Ausg. A|May 1, 1997
[Therapy with mitomycin C, folic acid and 5-fluorouracil in treatment of metastatic, refractory urinary bladder carcinoma--phase II study]T Otto, S Krege, B Otto, et al.Pageof 19